Sarepta Therapeutics, Inc.
SRPT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,898,962 | $1,675,886 | $6,213,643 | $11,707,050 |
| - Cash | $613,077 | $510,598 | $240,867 | $1,103,010 |
| + Debt | $1,250,188 | $1,353,877 | $1,343,749 | $1,343,070 |
| Enterprise Value | $2,536,073 | $2,519,165 | $7,316,525 | $11,947,110 |
| Revenue | $399,356 | $611,091 | $744,856 | $658,412 |
| % Growth | -34.6% | -18% | 13.1% | – |
| Gross Profit | $236,360 | $458,533 | $607,292 | $526,108 |
| % Margin | 59.2% | 75% | 81.5% | 79.9% |
| EBITDA | -$181,828 | $169,706 | -$369,037 | $186,673 |
| % Margin | -45.5% | 27.8% | -49.5% | 28.4% |
| Net Income | -$179,947 | $196,892 | -$447,508 | $159,049 |
| % Margin | -45.1% | 32.2% | -60.1% | 24.2% |
| EPS Diluted | -1.795 | 1.89 | -4.6 | 1.5 |
| % Growth | -195% | 141.1% | -406.7% | – |
| Operating Cash Flow | $0 | $261,337 | -$583,437 | $92,046 |
| Capital Expenditures | $0 | -$29,558 | -$45,889 | -$38,082 |
| Free Cash Flow | $0 | $231,779 | -$629,326 | $53,964 |